Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis
Abstract Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FDA approval in an inner-city tertiary center in the Bronx. Eight patients (80%) had received ≥ 3 lines of therapy, six patients had received prior radiation, and seven had recurrent disease after prior autologous hematopoietic stem cell transplant (AHCT). Our cohort included one patient with HIV, two patients with hepatitis B, and two patients with CNS involvement of lymphoma. Axi-cel treatment led to significant responses with 8/10 patients achieving a complete remission at 3 months, including both patients with prior CNS involvement. The treatment was generally well tolerated with 20% of patients experiencing grade ≥ 2 CRS. One patient each with HIV and hepatitis B responded without significant toxicities. In conclusion, Axi-cel led to significant efficacy with manageable toxicity in DLBCL in a real-world setting..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of hematology & oncology - 13(2020), 1 vom: 03. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abbasi, Ahmed [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Axi-cel |
|---|
| Anmerkungen: |
© The Author(s). 2020 |
|---|
| doi: |
10.1186/s13045-019-0838-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR029625378 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR029625378 | ||
| 003 | DE-627 | ||
| 005 | 20230519170314.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13045-019-0838-y |2 doi | |
| 035 | |a (DE-627)SPR029625378 | ||
| 035 | |a (SPR)s13045-019-0838-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abbasi, Ahmed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s). 2020 | ||
| 520 | |a Abstract Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FDA approval in an inner-city tertiary center in the Bronx. Eight patients (80%) had received ≥ 3 lines of therapy, six patients had received prior radiation, and seven had recurrent disease after prior autologous hematopoietic stem cell transplant (AHCT). Our cohort included one patient with HIV, two patients with hepatitis B, and two patients with CNS involvement of lymphoma. Axi-cel treatment led to significant responses with 8/10 patients achieving a complete remission at 3 months, including both patients with prior CNS involvement. The treatment was generally well tolerated with 20% of patients experiencing grade ≥ 2 CRS. One patient each with HIV and hepatitis B responded without significant toxicities. In conclusion, Axi-cel led to significant efficacy with manageable toxicity in DLBCL in a real-world setting. | ||
| 650 | 4 | |a CD19 CAR-T |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a HIV and CD-19 CAR-T |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a CNS and CD-19 CAR-T |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Axi-cel |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hepatitis B and CD-19 CAR-T |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Peeke, Stephen |4 aut | |
| 700 | 1 | |a Shah, Nishi |4 aut | |
| 700 | 1 | |a Mustafa, Jennat |4 aut | |
| 700 | 1 | |a Khatun, Fariha |4 aut | |
| 700 | 1 | |a Lombardo, Amanda |4 aut | |
| 700 | 1 | |a Abreu, Michelly |4 aut | |
| 700 | 1 | |a Elkind, Richard |4 aut | |
| 700 | 1 | |a Fehn, Karen |4 aut | |
| 700 | 1 | |a de Castro, Alyssa |4 aut | |
| 700 | 1 | |a Wang, Yanhua |4 aut | |
| 700 | 1 | |a Derman, Olga |4 aut | |
| 700 | 1 | |a Nelson, Randin |4 aut | |
| 700 | 1 | |a Uehlinger, Joan |4 aut | |
| 700 | 1 | |a Gritsman, Kira |4 aut | |
| 700 | 1 | |a Sica, R. Alejandro |4 aut | |
| 700 | 1 | |a Kornblum, Noah |4 aut | |
| 700 | 1 | |a Mantzaris, Ioannis |4 aut | |
| 700 | 1 | |a Shastri, Aditi |4 aut | |
| 700 | 1 | |a Janakiram, Murali |4 aut | |
| 700 | 1 | |a Goldfinger, Mendel |4 aut | |
| 700 | 1 | |a Verma, Amit |4 aut | |
| 700 | 1 | |a Braunschweig, Ira |4 aut | |
| 700 | 1 | |a Bachier-Rodriguez, Lizamarie |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of hematology & oncology |d London : Biomed Central, 2008 |g 13(2020), 1 vom: 03. Jan. |w (DE-627)SPR029612055 |w (DE-600)2429631-4 |x 1756-8722 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2020 |g number:1 |g day:03 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13045-019-0838-y |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2020 |e 1 |b 03 |c 01 | ||